AMBI
This article was originally published in The Tan Sheet
Executive Summary
Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)
You may also be interested in...
Chromax Chromium Picolinate Patent Infringement Alleged By AMBI
Nutrition 21 "will continue to seek legal remedies" against companies infringing on its Chromax chromium picolinate use patents, the AMBI subsidiary said May 9, while announcing the latest in a series of suits that began last August.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands